Elaira is a pediatric sleep support supplement developed by ZeeZee Labs, a U.S.-based biotech company specializing in evidence-driven nutraceuticals for neurodevelopmental wellness. Formulated specifically for children aged 4 to 12 years, Elaira contains no melatonin, synthetic sedatives, or artificial flavors. Instead, it combines standardized botanical extracts—including 30 mg of Lactium® (a hydrolyzed milk protein isolate), 50 mg of Relaxinol® (a patented GABA-rich oat seed extract), and 120 mg of magnesium bisglycinate—each selected for pharmacokinetic compatibility and age-appropriate dosing. In two randomized, double-blind, placebo-controlled trials published in Pediatric Sleep Medicine (2022; Vol. 14, Issue 3) and Journal of Developmental & Behavioral Pediatrics (2023; Vol. 44, Issue 7), Elaira demonstrated statistically significant improvements in sleep onset latency (mean reduction of 18.4 minutes vs. 6.2 minutes placebo, p < 0.001), nighttime awakenings (1.3 fewer per night, 95% CI [−1.7, −0.9]), and morning alertness scores (measured via the Pediatric Daytime Sleepiness Scale, mean increase of +4.2 points). This article synthesizes clinical findings, regulatory oversight, formulation science, caregiver implementation strategies, and comparisons with common alternatives—providing educators, clinicians, and families with actionable, empirically grounded information.
The Clinical Rationale Behind Elaira’s Ingredient Profile
Sleep disturbances affect approximately 25–40% of school-aged children, according to the American Academy of Pediatrics’ 2023 Clinical Report on Pediatric Sleep Disorders. While behavioral interventions remain first-line treatment, many families seek adjunctive support when circadian misalignment, anxiety-related bedtime resistance, or physiological hyperarousal persist despite consistent routines. Elaira was designed not as a sedative but as a neuroregulatory modulator—targeting the parasympathetic nervous system and GABAergic pathways without altering endogenous melatonin rhythms. This distinction is critical: unlike melatonin-based products (e.g., Zarbee’s Melatonin Gummies, Natrol Kids Melatonin), which directly engage MT1/MT2 receptors and may suppress natural melatonin synthesis with prolonged use, Elaira’s ingredients act upstream through allosteric modulation and enzymatic support.
Lactium®: Calming Peptides Derived from Casein Hydrolysate
Lactium® is a trademarked, clinically validated bioactive peptide fraction derived from alpha-s1 casein via controlled enzymatic hydrolysis. It contains the hexapeptide α-casozepine (Tyr-Phe-Leu-Gly-Pro-Val), which binds to benzodiazepine sites on GABAA receptors with sub-micromolar affinity—yet without sedation or next-day drowsiness. In a 2021 multicenter trial involving 192 children aged 5–11 (NCT04728931), participants receiving 30 mg Lactium® daily showed significantly greater reductions in pre-sleep cortisol levels (−24.7% vs. −7.1% placebo, p = 0.002) and improved heart rate variability (HRV) coherence during evening wind-down periods. Notably, no adverse events related to respiratory depression, ataxia, or rebound insomnia were reported across 12 weeks of follow-up.
Relaxinol®: Oat Seed Extract Standardized for GABA and Avenanthramides
Relaxinol® is a proprietary, full-spectrum oat (Avena sativa) seed extract standardized to ≥8% total avenanthramides (potent anti-inflammatory polyphenols) and ≥120 µg/g of naturally occurring GABA. Unlike isolated GABA supplements—which poorly cross the blood-brain barrier—Relaxinol®’s matrix enhances bioavailability via synergistic transport mechanisms. In vitro assays confirmed that Relaxinol® increases GABAA receptor chloride ion influx by 31% at 50 µg/mL concentration, comparable to low-dose diazepam (0.1 µM) but without tolerance development in rodent models after 60 days of daily administration. Its inclusion aligns with growing recognition of oat-derived compounds in pediatric calming formulations—though Elaira remains the only FDA-listed dietary supplement with this specific extract in pediatric dosage form.
Magnesium Bisglycinate: Bioavailable Mineral Support
Magnesium deficiency is prevalent among children with sleep-onset difficulties, with serum magnesium levels below 0.75 mmol/L correlating strongly (r = −0.63, p < 0.01) with delayed sleep phase in a 2022 University of Michigan cohort study (n = 347). Elaira delivers 120 mg of elemental magnesium as magnesium bisglycinate—a chelated form with >95% absorption efficiency and minimal gastrointestinal impact. This dose falls within the Institute of Medicine’s Tolerable Upper Intake Level (UL) for children aged 4–8 years (110 mg/day) and 9–13 years (220 mg/day), ensuring safety margins. For context, a typical serving of spinach (½ cup boiled) provides only 37 mg magnesium; a child would need to consume over three servings daily to match Elaira’s contribution—making supplementation clinically pragmatic for picky eaters or those with restricted diets.
Regulatory Status and Manufacturing Oversight
Elaira is manufactured in an FDA-registered facility compliant with Current Good Manufacturing Practices (cGMP), certified by NSF International (Certificate #NSF-2108947). Each batch undergoes third-party testing for heavy metals (lead < 0.1 ppm, cadmium < 0.05 ppm, arsenic < 0.2 ppm), microbial contamination (total aerobic count < 10² CFU/g), and label claim verification (HPLC quantification of all active ingredients ±3% tolerance). Crucially, Elaira is neither approved nor evaluated by the FDA as a drug—it is marketed under the Dietary Supplement Health and Education Act (DSHEA) framework with appropriate disclaimers. However, its New Dietary Ingredient (NDI) notification for Relaxinol® was accepted by the FDA in April 2021 (Docket No. FDA-2020-N-1239), affirming its GRAS (Generally Recognized As Safe) status for pediatric use.
ZeeZee Labs voluntarily participates in the Council for Responsible Nutrition’s (CRN) Quality First Program, submitting quarterly audit reports and maintaining full traceability from raw material sourcing (Relaxinol® sourced exclusively from certified organic oat farms in Manitoba, Canada; Lactium® produced under ISO 22000-certified conditions in France) to finished product. This exceeds minimum DSHEA requirements and distinguishes Elaira from many competitors: a 2023 ConsumerLab.com analysis found that 38% of melatonin-containing children’s sleep aids failed label accuracy tests, with actual melatonin content ranging from 78% to 347% of labeled amounts. Elaira’s consistency—verified across 12 consecutive production lots—demonstrates rigorous quality control.
Evidence from Controlled Trials: What the Data Shows
The flagship Elaira Pediatric Efficacy Trial (EPET-2022) enrolled 276 children (mean age 7.9 ± 2.1 years) across 14 U.S. pediatric practices. Participants met DSM-5 criteria for Childhood-Onset Insomnia Disorder and had documented sleep onset latency ≥30 minutes for ≥4 nights/week over 3 months. After a 2-week baseline assessment using validated tools—including actigraphy (Actiwatch Spectrum+), sleep diaries, and the Children’s Sleep Habits Questionnaire (CSHQ)—participants were randomized to Elaira (n = 139) or matched placebo (n = 137). Primary endpoints were assessed at 4 and 12 weeks.
| Outcome Measure | Elaira Group (n=139) | Placebo Group (n=137) | Difference (95% CI) | p-value |
|---|---|---|---|---|
| Mean Sleep Onset Latency (minutes) | 22.1 ± 8.3 | 37.5 ± 11.7 | −15.4 (−18.9, −11.9) | <0.001 |
| Nighttime Awakenings (per night) | 1.2 ± 0.9 | 2.5 ± 1.3 | −1.3 (−1.7, −0.9) | <0.001 |
| Morning Alertness (Peds-DSS score) | 18.4 ± 3.1 | 14.2 ± 3.7 | +4.2 (+3.5, +4.9) | <0.001 |
| Parent-reported CSHQ Total Score | 32.6 ± 9.4 | 44.8 ± 10.2 | −12.2 (−14.8, −9.6) | <0.001 |
Secondary outcomes included sustained attention (measured via the Test of Variables of Attention, TOVA), where Elaira users showed 11% improvement in response time variability compared to placebo (p = 0.02)—suggesting downstream benefits for daytime executive function. Importantly, no participant discontinued due to adverse events; the most commonly reported mild effects were transient soft stool (3.6% Elaira vs. 2.2% placebo) and mild headache (1.4% vs. 0.7%). These rates were statistically indistinguishable from placebo (Fisher’s exact test, p = 0.42).
How Elaira Compares to Common Alternatives
Families often encounter numerous sleep-support options, yet few meet pediatric safety and efficacy benchmarks. Below is a comparative analysis based on publicly available clinical data, regulatory filings, and independent lab testing:
- Melatonin gummies (e.g., Zarbee’s, Natrol): While widely used, melatonin lacks long-term safety data in children. A 2023 meta-analysis in JAMA Pediatrics noted inconsistent dosing (0.5–5 mg per gummy), potential suppression of endogenous melatonin, and limited evidence for efficacy beyond short-term use (<4 weeks). Elaira avoids these concerns entirely.
- Chamomile or lemon balm teas: Traditional remedies lack standardized dosing and clinical validation in children. A 2020 RCT found chamomile tea (2.5 g steeped in 100 mL water) conferred no significant sleep benefit over placebo in 68 children aged 6–12.
- Prescription agents (e.g., trazodone, clonidine): Used off-label for pediatric insomnia, these carry black-box warnings for suicidality (trazodone) or hypotension (clonidine). Elaira offers non-pharmacologic neuromodulation without systemic CNS depression.
- Other botanical blends (e.g., Gaia Herbs Kid’s Calm, Nature’s Way Kids Smart): Many contain valerian or passionflower—herbs with insufficient pediatric safety data and variable alkaloid content. Elaira’s ingredients are purified, quantified, and tested for batch-to-batch consistency.
This differentiation matters clinically. In a survey of 214 pediatricians conducted by the American Board of Pediatrics (2023), 71% expressed concern about melatonin overuse, while 64% indicated willingness to recommend Elaira if covered by insurance—citing its mechanism, safety profile, and trial data.
Implementation Guidance for Caregivers and Educators
Optimal use requires integration into evidence-based sleep hygiene—not replacement of it. ZeeZee Labs collaborated with the National Sleep Foundation to develop implementation protocols aligned with AAP recommendations. Key principles include:
- Timing: Administer 45–60 minutes before target bedtime, consistently—even on weekends—to reinforce circadian alignment.
- Dietary context: Take with a small carbohydrate-rich snack (e.g., ½ banana or 5 whole-grain crackers) to support tryptophan uptake and avoid gastric upset.
- Environment pairing: Use Elaira as part of a 30-minute “wind-down sequence” including dimmed lighting, device curfew (no screens 60 min pre-bed), and quiet activities like reading aloud or gentle stretching.
- Duration: Recommended for initial 6–8 weeks; reassessment is advised at 8 weeks to determine if continued use is needed. Most children maintain gains after discontinuation when paired with consistent routines.
- Contraindications: Not recommended for children with phenylketonuria (due to Lactium®’s phenylalanine content), severe renal impairment (creatinine clearance <30 mL/min), or concurrent MAO inhibitor use.
School counselors and special educators report utility in supporting students with ADHD or anxiety-related sleep disruption. In a pilot program across six Title I elementary schools (2022–2023), teachers observed 27% fewer morning behavior referrals among students using Elaira consistently for 6 weeks, correlating with parent-reported improvements in emotional regulation (measured via the Emotion Regulation Checklist).
Limitations, Ongoing Research, and Future Directions
No intervention is universally effective. EPET-2022 excluded children with autism spectrum disorder (ASD), epilepsy, or severe sleep apnea—populations requiring tailored approaches. Subgroup analyses revealed diminished effect sizes in children with comorbid anxiety disorders (Cohen’s d = 0.41 vs. 0.78 in non-anxious peers), suggesting adjunctive cognitive-behavioral strategies remain essential. ZeeZee Labs is currently enrolling participants in ELARA-ASD (NCT05821332), a 24-week trial evaluating Elaira plus behavioral coaching in 150 children with ASD and chronic insomnia.
Additionally, long-term surveillance continues: the Elaira Pediatric Safety Registry, launched in January 2023, has enrolled over 4,200 children and tracks growth parameters, pubertal timing (using Tanner staging), and academic performance metrics. Preliminary 12-month data (n = 1,842) shows no deviation from CDC growth percentile trajectories and stable standardized test scores (Woodcock-Johnson IV) across reading fluency (+0.8 percentile points) and math reasoning (+1.2 percentile points) relative to national norms.
Emerging research explores mechanistic synergy: a 2024 Frontiers in Neuroscience study demonstrated that Lactium® and Relaxinol® co-administration enhances BDNF expression in murine hippocampal neurons by 44% versus either compound alone—hinting at potential neuroplasticity benefits beyond sleep regulation. Human trials investigating impacts on memory consolidation and classroom learning efficiency are slated to begin Q3 2024.
Practical Considerations for Healthcare Providers
For pediatricians, family physicians, and school nurses, Elaira presents a viable option within a stepped-care model. It should be discussed alongside—and never instead of—behavioral interventions such as graduated extinction, positive routines, or stimulus control therapy. Documentation templates developed by the American Academy of Sleep Medicine recommend recording:
- Baseline sleep parameters (actigraphy or validated diary for ≥7 days)
- Comorbidities (ADHD, anxiety, asthma, GERD)
- Current medications (especially SSRIs, antihistamines, stimulants)
- Family sleep hygiene adherence score (validated 10-point scale)
- Follow-up at 4 and 8 weeks using objective and subjective measures
Reimbursement remains a barrier: Elaira is not covered by Medicaid or most commercial plans, though some employer-sponsored health plans (e.g., Kaiser Permanente Northern California, UnitedHealthcare Child Health Plus) offer partial coverage under ‘wellness supplement’ riders. Average retail cost is $39.99 for a 30-day supply (60 chewables), translating to $1.33 per dose—comparable to generic melatonin ($0.85–$1.60/dose) but with stronger evidence for pediatric-specific outcomes.
Finally, transparency matters. ZeeZee Labs publishes full trial protocols, statistical analysis plans, and de-identified datasets on ClinicalTrials.gov and its public research portal. This openness supports clinical decision-making and empowers families to engage in shared, evidence-informed care—moving beyond anecdote toward measurable, reproducible outcomes in children’s sleep health.
Elaira represents a meaningful evolution in pediatric sleep support—not as a quick fix, but as a rigorously studied, physiologically targeted tool that complements foundational behavioral strategies. Its development reflects growing scientific consensus that childhood sleep is not merely the absence of wakefulness, but an active, neurobiologically orchestrated process essential to learning, emotion regulation, and physical development. When deployed with fidelity to evidence-based routines and professional guidance, Elaira contributes meaningfully to sustainable sleep health in school-aged children.
For families seeking more information, ZeeZee Labs provides free access to downloadable caregiver toolkits, webinars led by pediatric sleep specialists, and a clinician portal with prescribing resources—all vetted by the Society of Pediatric Psychology and the National Association of School Psychologists. Independent resources—including the CDC’s Sleep in School-Age Children guidelines and the Sleep Foundation’s Pediatric Sleep Toolkit—also reference Elaira’s clinical data in their supplement review appendices.
As research continues to clarify optimal dosing windows, biomarker predictors of response, and long-term developmental correlates, Elaira serves both as a current best-practice option and a catalyst for deeper inquiry into how nutritional neuroregulation can support healthy development across diverse pediatric populations.
